International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Emerging infections and Biosecurity - Mohammed Lamorde, FRCP, PhD

Video

HIV

Viral Hepatitis and Liver Disease

Role of Pharmacology of selection COVID candidates - Andrew Owen, BSS, MSC, PhD, FSB

Video

HIV

Viral Hepatitis and Liver Disease

Steady-State Plasma TFV/FTC Among Adolescent Transgender Men and Women Receiving Directly Observed Daily TDF/FTC - Jenna Yager

Video

HIV

Viral Hepatitis and Liver Disease

Plasma and Breastmilk Pharmacokinetics of Tenofovir Using Dried Blood and Breast Milk Spots in HIV Infected Postpartum Women in Uganda - Letisha Najjemba

Video

HIV

Viral Hepatitis and Liver Disease

Population Pharmacokinetics of HIV-Specific Broadly Monoclonal Neutralizing Long-Acting Antibody, VRC01LS, in Term Infants - Jincheng Yang

Video

HIV

Viral Hepatitis and Liver Disease

In-Silico Prediction of Intramuscular Long-Acting Rilpivirine in Liver Impairment With PBPK Models - Nicolas Cottura

Video

HIV

Viral Hepatitis and Liver Disease

Poster Presentations - Kashuba, Dumitrescu, Patel, Moore, Pastagia, Kakuda, Vandenbossche

Video

HIV

Viral Hepatitis and Liver Disease

Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age - Mina Nikanjam

Video

HIV

Viral Hepatitis and Liver Disease

A Population Pharmacokinetic Analysis Assessing the Exposure of Raltegravir Once-Daily 1200mg in Pregnant Women Living With HIV - Vera Bukkems

Video

HIV

Viral Hepatitis and Liver Disease

Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets - Rajendra Singh

Video

HIV

Viral Hepatitis and Liver Disease

Poster Presentations - Elsherif, Kinvig, Cindi, Rawizza, George

Video

HIV

Viral Hepatitis and Liver Disease

A Phase 3, Open-label, Dose Escalation study to determine the pharmacokinetics of Atazanavir administered with RIfampicin to HIV positive adults on sEcond-line ART regimen with suppressed HIV-1 viral load (DERIVE): Scheduled Interim Analysis

International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020

Emerging infections and Biosecurity - Mohammed Lamorde, FRCP, PhD

Role of Pharmacology of selection COVID candidates - Andrew Owen, BSS, MSC, PhD, FSB

FDA perspective on COVID-19 - Kimberly Struble, PharmD

Pharmacology of bNABs - Edmund Capparelli, PharmaD

Clinical Pharmacology Long Acting ARVs - Marta Boffito, MD, PhD, FRCP

Development of Novel Formulations/Devices - Charles Flexner, MD

Transporters mediated DDI's - Vikram Arya, PhD, FCP

Role of herbal in DDIs - Dario Cattaneo, PharmD, PhD

Steady-State Plasma TFV/FTC Among Adolescent Transgender Men and Women Receiving Directly Observed Daily TDF/FTC - Jenna Yager

Plasma and Breastmilk Pharmacokinetics of Tenofovir Using Dried Blood and Breast Milk Spots in HIV Infected Postpartum Women in Uganda - Letisha Najjemba

Population Pharmacokinetics of HIV-Specific Broadly Monoclonal Neutralizing Long-Acting Antibody, VRC01LS, in Term Infants - Jincheng Yang

In-Silico Prediction of Intramuscular Long-Acting Rilpivirine in Liver Impairment With PBPK Models - Nicolas Cottura

Poster Presentations - Kashuba, Dumitrescu, Patel, Moore, Pastagia, Kakuda, Vandenbossche

Impact of CYP2B6 Genotype, TB Therapy and Formulation on Efavirenz Pharmacokinetics in Infants and Children Under 40 Months of Age - Mina Nikanjam

A Population Pharmacokinetic Analysis Assessing the Exposure of Raltegravir Once-Daily 1200mg in Pregnant Women Living With HIV - Vera Bukkems

Comparison of Relative Bioavailability of TIVICAY Neonatal Liquid Formulations to Pediatric Dispersible Tablets - Rajendra Singh

Poster Presentations - Elsherif, Kinvig, Cindi, Rawizza, George

A Phase 3, Open-label, Dose Escalation study to determine the pharmacokinetics of Atazanavir administered with RIfampicin to HIV positive adults on sEcond-line ART regimen with suppressed HIV-1 viral load (DERIVE): Scheduled Interim Analysis